The therapeutics pipeline of chronic kidney disease has been increasing on account of rising prevalence of diabetes and high blood pressure in patients. The diabetes and blood pressure are the main causes of chronic kidney disease, which is also related to cardiovascular disease. Due to altered lifestyle, the chances of incidence of high blood pressure and diabetes is on a rise. Currently, the prevalence of chronic kidney disease is around 14% in Australia, as studied by Oxford Academic Journal of Nephrology Dialysis Transplantation. According to, National Institute of Diabetes and Digestive and Kidney Disease, the number of kidney failure cases among the Americans stood at more than 661,000, out of which 468,000 patients are undergoing dialysis and 193,000 patients are living with functional kidney transplant. The increasing awareness of healthcare issues also contributes towards the of development of therapeutics pipeline for chronic kidney disease.
Chronic kidney disease is the condition that can lead to the damage of the kidneys. Some of the main symptoms of chronic kidney disease are, weight loss, insomnia, tiredness, blood in urine, feeling sick, muscle cramps shortness of breath.
Many companies are conducting clinical trials for the development of therapeutics for chronic kidney disease. Astellas Pharma, Inc., is in the process of introducing a drug by the name ASP1517, which is in Phase III stage of its clinical development. ASP1517 is an orally administered small molecule which is used for the treatment of anaemia associated with chronic kidney disease. AstraZeneca Plc is also introducing a drug named, Dapagliflozin, which is currently in its Phase III stage of clnical development. Dapagliflozin is a sodium-glucose cotransporter II inhibitor.
In April 2016, Boehringer Ingelheim GmbH and Ablynx NV initiated the Phase I study to evaluate safety, tolerability and pharmacokinetics of single ascending dose of an anti-CX3CR1 Nanobody administered intravenously. Ablynx NV would receive €8 million as milestone payment. This anti-CX3CR1 Nanobody blocks the function of G-protein coupled receptor, which leads to inhibition of inflammatory immune cells that play an important role in chronic kidney disease. In February 2016, AstraZeneca Plc and MedImmune, LLC entered into a collaboration with University of Michigan and Eli Lilly and company for the development of new therapies of chronic kidney disease. In September 2014, Covance Inc. a leading global drug development services company, and Frenova Renal Research entered into a collaboration to find the more effective treatment for patients living with end stage renal disease and chronic kidney disease. In September 2016, Evotec AG and Bayer AG entered into a five-year collaboration agreement for the development of multiple clinical candidates for chronic kidney disease in diabetic patients. Both the companies would contribute towards the technology platform to develop innovative treatment options for severe conditions of chronic kidney disease.
Some of the companies having a pipeline of chronic kidney disease therapeutics include Astellas Pharma Inc., AstraZeneca Plc, Proteon Therapeutics, Inc., RegenMed (Cayman) Ltd, Gilead Sciences, Inc., GlaxoSmithKline Plc, Relypsa, Inc., Chugai Pharmaceutical, Inc., Kissei Pharmaceutical Co., Ltd, Boryung Pharmaceutical Co., Ltd.